Winter fuel payment in Scotland to match UK benefit
The Scottish Government's devolved version of the winter fuel payment will match the value of the UK benefit, John Swinney has announced.
Chancellor Rachel Reeves confirmed last week that the payment would be reinstated to the majority of pensioners.
Following the initial decision to cut the universal benefit, the Scottish Government was forced to delay its plans for the pension age winter heating payment, but in December it announced pensioners north of the border would receive at least £100 every year.
Speaking in Glasgow on Monday, the First Minister confirmed the Scottish Government's benefit would at least match that proposed by the UK Government.
Pensioners south of the border who earn under £35,000 will receive either £200 or £300.
'I'm very happy to confirm today that no pensioner in Scotland will receive less than they would under the new UK scheme,' he said.
'Details will be set out in due course by my Government, but the Scottish Government will always seek to do what is best for Scotland's pensioners.'
The changes announced last week will result in further increases in funding for the Scottish Government, which the First Minister later told journalists is expected to be around £120 million.
Speaking at an event on public sector reform on Monday, the First Minister hit out at the initial decision to cut the benefit.
'To be quite blunt about it, I don't believe cutting this winter lifeline was ever going to save a penny,' he said.
'Making millions of pensioners poorer makes them also colder and makes them also sicker, and that in turn puts up the bill for our social services and our NHS.'
He added: 'It's one of the reasons we were so quick to step in to protect pensioners in Scotland as best as we could from that wrong decision by the UK Government.
'But now that they've seen the error of their ways, my Government will once again to the right thing by Scotland's pensioners.'
The power over the payment was devolved to Social Security Scotland in time for it to be paid out last winter. When asked if he regretted not offering it to older Scots, the First Minister said: 'I might have had the power, but I didn't have the money and I can't spend money I don't have.
'If the UK Government cuts a budget, I can't spend it, and what we've done is we've taken a series of hard decisions to allow us, before the Labour Government came anywhere near doing a U-turn on this, to restore winter fuel payments to pensioners because of other hard decisions that I've made.
'So the SNP has kept faith with pensioners in Scotland when the Labour Party has deserted them.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
18 minutes ago
- Times
The Casey report: the authorities had a culture of denial
Disproportionate numbers of Asian men have been responsible for child sex grooming gangs, but successive governments covered up the fact for fear of racism or raising tensions, a report has found. The national audit of grooming gangs, by Baroness Casey of Blackstock, found that flawed data had been used repeatedly to dismiss claims about Asian grooming gangs as sensationalised, biased or untrue, while an institutional view persisted that there was an overwhelming problem with white perpetrators when, in fact, that could not be proved. Casey pointed to a culture of denial that meant governments, police and local authorities had avoided the issue of ethnicity 'for fear of appearing racist, raising community tensions or causing community cohesion problems'.
Reuters
18 minutes ago
- Reuters
Ireland to sell final AIB shares 15 years after banking crisis
DUBLIN, June 16 (Reuters) - The Irish government on Monday launched the sale of its remaining shares in AIB Group (AIBG.I), opens new tab, one of the country's two dominant lenders it effectively nationalised 15 years ago, Finance Minister Paschal Donohoe said. Ireland pumped 64 billion euros ($74.10 billion) or almost 40% of its then annual economic output, into the country's banks after a huge property crash in the late 2000s stemming from the global financial crisis. Two banks that swallowed up more than half of the capital still failed. Most of the remaining funds - 21 billion euros - went into AIB and the state's return from the bank stood at 19.2 billion euros last month when its shareholding dropped to 3.3%. AIB is also it talks to buy back stock warrants the government holds in the bank. The transaction will leave Ireland with a 57% stake in the smaller Permanent TSB (PTSB.I), opens new tab to sell to complete its long withdrawal from the sector. It sold the last of its shares in AIB's chief rival Bank of Ireland (BIRG.I), opens new tab in 2022. "This is an important milestone in delivering on the policy of returning the banking sector to private ownership," Donohoe said, announcing the sale of the state's final 2% holding by way of an accelerated bookbuild transaction. The government has sold small amounts of shares between its bigger transactions, resulting in the now 2% holding. Books on the transaction are covered, a bookrunner on the deal said shortly after it was announced. While Dublin is unlikely to fully recoup the cost of bailing out AIB, Donohoe said last month the state was at that point 300 million euros above break-even on its 29.4 billion investment in the three banks, mainly thanks to recovering 6.7 billion euros from the 4.7 billion it pumped into Bank of Ireland. The government removed a 500,000 euro pay cap from Bank of Ireland after completing a review of the sector's pay restrictions shortly after the bank returned to full private ownership. The cap remained in place for AIB and Permanent TSB. ($1 = 0.8637 euros)
Telegraph
44 minutes ago
- Telegraph
Trump to force NHS to pay for wonder drugs
NHS patients have been given new hope of accessing wonder drugs previously blocked in Britain as Donald Trump pressures the health service to spend more with US suppliers. Ministers are understood to be reviewing the value-for-money rules that govern which drugs the NHS can buy, amid demands from the Trump administration for the UK to be more welcoming to US pharmaceutical companies. Under the trade agreement signed between the two nations earlier this year, the Government agreed to 'endeavour to improve the overall environment for pharmaceutical companies operating in the UK'. Earlier this week, The Telegraph revealed that this could result in the NHS paying more for US drugs to see off criticism of the differences in medicine prices between the two nations. However, it is understood that discussions include not only paying more for treatments already supplied on the NHS but also making it easier for US drug giants to sell their most cutting-edge treatments to the health service. It follows a wave of high-profile rejections of so-called 'wonder' drugs in recent years. The National Institute of Health and Care Excellence (Nice), which approves new NHS drugs for purchase, has blocked treatments including one which stopped the progression of Alzheimer's disease and another that doubled the life expectancy for terminal breast cancer patients. Nice has rejected them based on assessments of how long they would extend a patient's lifespan and improve quality of life. To qualify under Nice rules a new treatment must deliver one extra year of perfect health, or longer for less perfect health, for no more than £30,000. This figure has not increased in line with inflation since 1999. If it had, it would be just over £53,000. Nice has maintained that, to get approval for use on the NHS, medicines 'must not only provide benefits to patients but also represent a good use of NHS resources and taxpayers' money'. However, critics say a failure to raise the threshold in-line with inflation meant life-changing drugs were being blocked. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said: 'There is growing evidence that it is becoming harder to bring new medicines to NHS patients. Increasingly, some new medicines may not be launched in the UK at all.' Companies including US giant Eli Lilly have said the regulator must rethink how 'value-for-money' is assessed. On Monday, a spokesman for the company said: 'The UK has historically focused on medicines as a cost to the NHS rather than evaluating their social and economic value.' Ministers are understood to be listening to demands from the industry for Nice to shake up its formula, with medicines such as AstraZeneca's breast cancer treatment Enhertu likely to be resubmitted for approval for NHS use if the formula is updated. Nice and AstraZeneca previously failed to reach an agreement over a price for the drug, which costs an estimated £118,000 per course of treatment. The NHS typically gets discounts, although the level is commercially sensitive. The Nice formula is being discussed after President Trump took a personal interest in the NHS issue. In trade documents between the US and UK, it said the NHS would review drug pricing to take into account the 'concerns of the president'. US officials are particularly concerned by an arrangement that sees companies pay revenue back to the NHS if costs rise faster than expected. Drug companies paid £3bn back to the NHS last year. In April, Wes Streeting, the Health Secretary, said he was proud that the UK had kept prices of medicines low. However, he admitted that the UK had become too focused on cost rather than the benefits in some cases. Mr Streeting said: 'We've moved from quite rightly trying to drive a good bargain on the price of drugs and treatment to a position where sometimes people view medicine spend as a dead weight cost'.
